← Eichor
Condition: Recurrent Adult T Cell Leukemia Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Adult T Cell Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
Phase 1/Phase 2 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06064903AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NA · 1 location(s) · Shenzhen University General Hospital · NCT05620680Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-
Phase 1/Phase 2 · 163 location(s) · SWOG Cancer Research Network · NCT04315324CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 · 2 location(s) · Rong Tao · NCT064458033'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05996185Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 · 1 location(s) · John Reneau · NCT04848064U69-CART-Cells For R/R T-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07350863HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044VHAG in Treating R/R T-ALL/LBL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06742463Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignanci
Phase 1/Phase 2 · 36 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05658640CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05442515A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Phase 1/Phase 2 · 5 location(s) · Otsuka Medical Devices Co., Ltd. Japan · NCT07075328HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.